Diabdana S.R.L.

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes10 trials
• Obesity4 trials
• Chronic kidney disease2 trials
• High blood pressure1 trial
• Obstructive sleep apnoea1 trial
• Stroke1 trial
• Type 1 diabetes1 trial

Phase

• Phase 310 trials
• Phase 42 trials

Status

• Completed6 trials
• Recruiting4 trials
• Active, not recruiting2 trials

Lead sponsor

• Eli Lilly and Company8 trials
• Novo Nordisk A/S2 trials
• Amgen Inc.1 trial
• Boehringer Ingelheim1 trial

Running trials

• Not yet recruiting

  A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

  NCT07931495· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  NCT07392190· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· Phase 3· Amgen Inc.· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

  NCT05433584· Phase 4· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 2 diabetes3 recruiting
• Chronic kidney disease1 recruiting
• High blood pressure1 recruiting
• Obesity1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

  NCT06534411· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

  NCT06109311· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

  NCT05929079· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

  NCT05564039· Phase 4· Eli Lilly and Company· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source